Biotech and Pharma

Morgan Stanley is bullish on the S&P 500 over the next year, and likes discretionary goods, healthcare, financials, industrials, and small-caps too.

It’s the only drug company ever to have a $1 trillion capitalization value; the other U.S. companies are tech giants and Berkshire Hathaway.

Nvidia turns lower as strong earnings fail to assuage concerns over an artificial-intelligence bubble.

Abbott Laboratories agrees to buy the cancer screening company for $105 a share in a cash deal.

Bristol Myers Squibb trades at seven times earnings, with multiple growth drivers.

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.

A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.

Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a difference.

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

The report comes after China pressured the U.S. by cutting exports of rare-earth minerals critical to autos, semiconductors and military equipment.

The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

Crypto caught in broad market selloff, food, restaurant companies feeling relief, U.S.-China trade deal is fragile, and more news to start your day.

Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”

The increase will soak up much of an increase in Social Security payments to account for inflation.

The companies’ drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.

Stocks turned mostly higher on Friday, rebounding from a brutal selloff.

Bristol said it had decided to stop one of its ongoing Phase 3 trials testing an experimental blood thinner called milvexian.

Cidara Therapeutics is developing a drug designed to prevent the flu.

Negative technical factors continue to weigh on markets.

Avery Marquez, IPO specialist at Renaissance Capital, offers advice for investors as the market for initial public offerings heats up again.

The sector is up almost 7% since the start of November, while the broader market is down more than 1%.

Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.

Dr. Richard Pazdur is “likely the best possible person for the role,” says one analyst. A calmer course for the FDA could add fuel to the recent run-up in biotech stocks.

BigBear.ai surges after striking a deal to acquire a generative AI platform, while Nebius falls after missing analysts’ estimates.

The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.